Quick Answer
enGene Therapeutics Inc. reported Shares Outstanding of 52.02 million shares for fiscal year 2025.
enGene Therapeutics Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 52.02M | +2.0% |
| 2024 | 50.98M | +119.7% |
| 2023 | 23.20M | +3384.4% |
| 2022 | 665,767 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | 66.99M | +31.4% | +28.8% |
| October 31, 2025 | 52.02M | +2.0% | +1.8% |
| July 31, 2025 | 51.11M | +15.6% | +0.1% |
| April 30, 2025 | 51.07M | +15.7% | +0.2% |
| January 31, 2025 | 50.98M | +119.8% | +0.0% |
| October 31, 2024 | 50.98M | +119.7% | +15.3% |
| July 31, 2024 | 44.22M | — | +0.1% |
| April 30, 2024 | 44.16M | — | +90.4% |
- enGene Therapeutics Inc. showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
- Over the 2022–2025 period, enGene Therapeutics Inc.’s shares outstanding has grown by 7713.3% (from 665.8 thousand shares to 52.02 million shares).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: